Clinical Trial: A First-in-human Study to Evaluate the Safety and Tolerability of HB-2121 as a Diagnostic for Celiac Disease

U.S., July 15 -- ClinicalTrials.gov registry received information related to the study (NCT07063823) titled 'A First-in-human Study to Evaluate the Safety and Tolerability of HB-2121 as a Diagnostic for Celiac Disease' on June 16.

Brief Summary: The goal of this clinical trial is to learn about the safety of a single dose of HB-2121 in adults. It will also look at how the body processes the drug. The main questions it aims to answer are:

* What side effects do participants have after receiving HB-2121?

* How much HB-2121 is in the blood over time?

Researchers will follow participants for 30 days after receiving HB-2121 to understand how the drug behaves in the body and how safe it is.

Participants will:

* Receive one oral dose of HB-2...